Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Randomized Control Study of Nedaplatin or Cisplatin Concomitant with Other Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

  • Li, Chun-Hong (Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Liu, Mei-Yan (Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Liu, Wei (Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Li, Dan-Dan (Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Cai, Li (Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital)
  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To observe the short-term efficacy, long-term survival time and adverse responses with nedaplatin (NDP) or cisplatin (DDP) concomitant with other chemotherapy in treating non-small cell lung cancer. Materials and Methods: A retrospective, randomized, control study was conducted, in which 619 NSCLC patients in phases III and IV who were initially treated and re-treated were randomly divided into an NDP group (n=294) and a DDP group (n=325), the latter being regarded as controls. Chemotherapeutic protocols (CP/DP/GP/NP/TP) containing NDP or DDP were given to both groups. Patients in both groups were further divided to evaluate the clinical efficacies according to initial and re-treatment stage, pathological pattern, type of combined chemotherapeutic protocols, tumor stage and surgery. Results: The overall response rate (ORR) and disease control rate (DCR) in the NDP group were 48.6% and 95.2%, significantly higher than in the DDP group at 35.1% and 89.2%, respectively (P<0.01). In NSCLC patients with initial treatment, squamous carcinoma and phase III, there were significant differences in ORR and DCR between the groups (P<0.05), while ORR was significant in patients with adenocarcinoma, GP/TP and in phase IIIa (P<0.05). There was also a significant difference in DCR in patients in phase IIIb (P<0.05). According to the statistical analysis of survival time of all patients and of those in clinical phase III, the NDP group survived significantly longer than the DDP group (P<0.01). The rates of decreased hemoglobin and increased creatinine, nausea and vomiting in the NDP group were evidently lower than in DDP group (P<0.05). Conclusion: NDP concomitant with other chemotherapy is effective for treating NSCLC, with higher clinical efficacy than DDP concomitant with chemotherapy, with advantages in prolonging survival time and reducing toxic and adverse responses.

Keywords

References

  1. Arriagada R, Bergman B, Dunant A, et al (2004). Cisplatin_based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med, 350, 351-60. https://doi.org/10.1056/NEJMoa031644
  2. Alberto ME, Lucas MF, Pavelka M, et al (2009). The secondgeneration anticancer drug Nedaplatin, atheoretical investigation on the hydrolysis mechanism. J Phys Chen B, 113, 14473-9. https://doi.org/10.1021/jp9056835
  3. Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years, analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
  4. Hotta K, Matsuo K, Ueoka H, et al (2004). Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplain in patients with advanced non-small-cell lung cancer. J Clin Oncol, 22, 3852-9. https://doi.org/10.1200/JCO.2004.02.109
  5. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistis, 2008. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
  6. Jin-ji Yang, Qing Zhou, Ri-qiang Liao, et al (2012). Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer, A Randomized Clinical Trial. Chin J Cancer Res, 24, 97-102. https://doi.org/10.1007/s11670-012-0097-8
  7. Kameyama Y, Okazaki N, Nakagawa M, et al (1990). Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett, 52, 15-24. https://doi.org/10.1016/0378-4274(90)90161-E
  8. Kim JL, Cho KH, Park EC, et al (2014). A single measure of cancer burden combining incidence with mortality rates for worldwide application. Asian Pac J Cancer Prev, 15, 433-9. https://doi.org/10.7314/APJCP.2014.15.1.433
  9. Liu J, Li N, Chang S, et al (2013). Characteristics of 240 Chinese father-child pairs with malignant disease. Asian Pac J Cancer Prev, 14, 6501-5. https://doi.org/10.7314/APJCP.2013.14.11.6501
  10. Maione P, Rossi A, Bareschino MA, et al (2011). Factors driving the choice of the best second-line treatment of advanced NSCLC. Rev Recent Clin Trials, 6, 44-51. https://doi.org/10.2174/157488711793980192
  11. Mandal SK, Singh TT, Sharma TD, et al (2013). Clinicopathology of lung cancer in a regional cancer center in Northeastern India. Asian Pac J Cancer Prev, 14, 7277-81. https://doi.org/10.7314/APJCP.2013.14.12.7277
  12. Niioka Z Uno Z Yasui-Furukori N, et al (2007). Pharmacokinetics of lowdose nedaplatin and validation of AUC prediction in patients with non-small cell lung carcinoma. Cancer Chemother Pharmacol, 59, 575-80. https://doi.org/10.1007/s00280-006-0298-2
  13. Oven Ustaalioglu BB, Unal OU, Turan N, et al (2013). Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer, multicenter experiences. Asian Pac J Cancer Prev, 14, 6287-92. https://doi.org/10.7314/APJCP.2013.14.11.6287
  14. Rinaldi M, Cauchi C, Gridelli C, et al (2006). First line chemotherapy in advanced or metastatic NSCLC. Ann OncoL, 17, V64-7. https://doi.org/10.1093/annonc/mdj953
  15. Sugiyama T, Hirose T, Nakashima M (2011). Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small cell lung cancer. Oncology, 81, 273-80. https://doi.org/10.1159/000334430
  16. Scagliotti GV, Parikh P'yon Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51. https://doi.org/10.1200/JCO.2007.15.0375
  17. Terret C, Albrand G, Moncenix G, et al (2011). Karnofsky Performance Scale (KPS) or Physical Performance Test (PPD? That is the question. Crit Rev Oncol Hematol, 77, 142-7. https://doi.org/10.1016/j.critrevonc.2010.01.015
  18. Teramoto K, AsadaY, Ozaki Y, et al (2012). A phase II study of docetaxel plus nedaplatin in patients with metastatic nonsmall-cell lung cancer. Cancer Chemother Pharmacol, 70, 531-7. https://doi.org/10.1007/s00280-012-1941-8
  19. Wagner TD, Yang GY (2010). The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). Curt Drug Targets, 1l, 67-73. https://doi.org/10.2174/138945010790030956
  20. Wagner TD, Yang GY (2006). The role of chemotherapy and radiation in the treatment of Belvedere O, Grossi F. Lung Cancer Highlights from ASCO 2005. Oncologist, 11, 39-50. https://doi.org/10.1634/theoncologist.11-1-39
  21. Yu DP, Han Y, Zhao QY, et al (2012). Pulmonary lobectomy combined with pulmonary arterioplasty by complete videoassisted thoracic surgery in patients with lung cancer. Asian Pac J Cancer Prev, 14, 6061-4. https://doi.org/10.7314/APJCP.2013.14.10.6061

Cited by

  1. Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3951
  2. Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells vol.10, pp.4, 2015, https://doi.org/10.1371/journal.pone.0124994
  3. Gemcitabine Plus Nedaplatin as Salvage Therapy is a Favorable Option for Patients with Progressive Metastatic Urothelial Carcinoma After Two Lines of Chemotherapy vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2483
  4. Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells vol.11, pp.4, 2016, https://doi.org/10.3892/ol.2016.4276